Organon & Co. (NYSE:OGN) Stake Raised by Stifel Financial Corp

Stifel Financial Corp lifted its holdings in shares of Organon & Co. (NYSE:OGN) by 71.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 405,528 shares of the company’s stock after buying an additional 169,447 shares during the period. Stifel Financial Corp owned approximately 0.16% of Organon & Co. worth $6,051,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in OGN. Horizon Bancorp Inc. IN boosted its position in Organon & Co. by 2,401.5% during the 4th quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock worth $25,000 after acquiring an additional 1,585 shares during the period. Millstone Evans Group LLC bought a new position in Organon & Co. in the 4th quarter valued at about $29,000. Larson Financial Group LLC grew its position in Organon & Co. by 345.4% in the 4th quarter. Larson Financial Group LLC now owns 2,236 shares of the company’s stock valued at $33,000 after buying an additional 1,734 shares in the last quarter. Riverview Trust Co increased its stake in Organon & Co. by 117.7% during the 4th quarter. Riverview Trust Co now owns 2,390 shares of the company’s stock valued at $36,000 after buying an additional 1,292 shares during the period. Finally, GeoWealth Management LLC bought a new stake in shares of Organon & Co. during the 4th quarter worth about $41,000. 77.43% of the stock is owned by institutional investors.

Organon & Co. Stock Performance

OGN opened at $13.21 on Wednesday. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm has a market cap of $3.41 billion, a PE ratio of 3.97, a P/E/G ratio of 0.90 and a beta of 0.73. The business has a fifty day simple moving average of $13.76 and a 200-day simple moving average of $15.09. Organon & Co. has a fifty-two week low of $10.45 and a fifty-two week high of $23.10.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The company had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. As a group, equities analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, March 13th. Investors of record on Monday, February 24th were given a $0.28 dividend. The ex-dividend date of this dividend was Monday, February 24th. This represents a $1.12 annualized dividend and a dividend yield of 8.48%. Organon & Co.’s dividend payout ratio (DPR) is presently 33.63%.

Analyst Ratings Changes

A number of research analysts recently commented on OGN shares. Barclays lowered their price objective on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. TD Cowen raised Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Morgan Stanley decreased their target price on Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $19.75.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.